31results about How to "No increase in toxicity" patented technology

The invention discloses a medicinal composition for treating or preventing the obesity and metabolic syndromes, and belongs to the medicine field. The medicinal composition treats orlistat and acarbose as medicinal active components, so the application amount of orlistat in the medicinal composition is substantially reduced, thereby the risk of the damage of orlistat to the liver of a body is reduced. The medicinal composition has a substantial synergistic effect when the medicinal composition is used for treating or preventing the obesity and the metabolic syndromes, can reduces the diabetes and angiocardiopathy suffering risks of obese patients, and has a wide medical application prospect.

The invention relates to a denatured protein powder and a brain protein hydrolyzate prepared from the same. The total nitrogen content of the denatured protein powder is more than 120 mg/g; and the denatured protein powder is prepared by adding fresh lysozyme into a pig brain, homogenating, heating, and defatting with acetone. The denatured protein powder, as a raw material, is used for preparingthe brain protein hydrolyzate; the contents of amino acids in the prepared brain protein hydrolyzate meet national standards of brain protein hydrolyzate injections; and the content of small moleculepeptides with the molecular weight of less than 10000 Da is 25-35% of the brain protein hydrolyzate. The preparation method of the brain protein hydrolyzate mainly comprises the following steps: pre-treating, homogenizing, defatting with the acetone, performing dual enzymatic hydrolysis, centrifugating, refining by column chromatography, and performing ultrafiltration treatment. The invention discloses key technical points for controlling the total nitrogen index of the protein powder and the content of the small molecule peptides for the first time; the obtained brain protein hydrolyzate is a biologically active substance which is really extracted from the pig brain, without adding active components artificially, thus ensuring the efficacy and the safety of the brain protein hydrolyzate;and animal pharmacodynamic experiments show that the brain protein hydrolyzate is more effective than conventional products.

The present invention relates to a medicine composition containing taxol-like substance. Its composition contains (by weight portion) 1 portion of taxol-live substance, 0.05-10 portions of organic acid, 0-10 portions of organic acid salt and proper quantity of cyclodextrin. Under the condition of that environmental temp. is not higher than 35 deg.C said invented medicine composition stability can be relained for above 6 hr, and can meet the requirements for intravenous drip therapy.

The invention relates to a bactericidal composition containing prothioconazole and trifloxystrobin, and the bactericidal composition consists of active components and pesticide preparations as auxiliary components; and especially, the active components consist of prothioconazole and trifloxystrobin in a weight proportion of (0.2-20):1. In the invention, the prothioconazole and the trifloxystrobin are compounded in a special proportion, so that a very significant synergistic interaction effect is obtained. A mass of experiments show that the toxicity to mammals is not increased after the prothioconazole and the trifloxystrobin are compounded. Furthermore, the applicant further discovers that the bactericidal composition containing prothioconazole and trifloxystrobin can be used for further promoting the compounding effect of the prothioconazole and the trifloxystrobin with the adoption of a special wetting dispersant and a dispersion wetting agent, so that both the prothioconazole and the trifloxystrobin play a synergistic role to a maximum extent.

The invention discloses a novel composition for treating hyperlipemia, which comprises effective dose of Nicotinic Acid and Atorvastatin calcium by the weight ratio is (30-240) : 1.

The invention discloses a medical composition for treating metabolic syndromes, belonging to the field of medicines, and in particular relates to a medical composition containing orlistat or cetilistat and actos, wherein the composition is solid preparations such as compressed tablets, dispersible tablets, sustained release tablets, capsules, granules, and the like. In experiments, the medical composition containing the orlistat or the cetilistat and the actos is accidentally found to have obvious synergistic effect on the aspects of reducing the blood pressure, the serum total cholesterol, the serum triglyceride and the low density lipoprotein cholesterin and enhancing the carbohydrate tolerance.

The invention relates to a ternary compound bactericidal composition and application thereof. The ternary compound bactericidal composition is composed of an active ingredient and a pesticide preparation auxiliary component, wherein the active ingredient is formed by compounding pyraclostrobin, metconazole and carbendazim together in a weight ratio of (0.05-1): (0.05-1.5): 1; and the pesticide preparation auxiliary component comprises compound sodium nitrophenolate accounting for 0.05-2% of the composition in mass percent. The ternary compound bactericidal composition is formed by compounding pyraclostrobin, metconazole and carbendazim together in a special ratio, thereby achieving very obvious synergistic interaction effect; and provided by lots of experiments, after compounding, toxicity on the mammal is not increased. Besides, the applicant further finds out the compounding effect of pyraclostrobin, metconazole and carbendazim can be further promoted in the special form of wetting dispersant and wetting dispersing agent according to the invention; and therefore, the synergistic effect of the three ingredients is developed to an utmost extent.

The invention relates to a pharmaceutical composition of Vinflunine, which comprises Vinflunine as the active constituent, pharmaceutically acceptable salts and cyclodextrin, wherein each 1 part of Vinflunine and its pharmaceutically acceptable salt are mixed with a maximum of 0. 5-100 parts by weight ratio of cyclodextrin, and freeze dried injection is prepared. The invention also relates to the process for preparing the composition, and its use in preparing non-stomach administering pharmaceutical products for the treatment of cancer.

The invention belongs to the field of medicines, and relates to a pharmaceutical composition containing lorcaserin and a medical application of the pharmaceutical composition, in order to overcome the deficiencies in the prior art that lorcaserin has a large adverse reaction in an obesity treatment process, and the effect of continuously losing weight is not good. The pharmaceutical composition has definite treatment effect and small adverse reaction when applied to obesity treatment, and has good therapeutic action on a metabolic syndrome, and good clinical application prospects.

The invention relates to a pharmaceutical composition for weight reduction or metabolic syndrome treatment, belongs to the field of medicine and particularly relates to a pharmaceutical composition containing orlistat or cetilistat and rosiglitazone hydrochloride, wherein the composition is of solid preparations such as common tablets, dispersible tablets, sustained release tablets, capsules and granules. An accidental discovery in experiments shows that the pharmaceutical composition containing orlistat or cetilistat and rosiglitazone hydrochloride is significantly synergistically functional in lowering blood sugar and reducing weight, a preparation method is simple, operating is convenient, and the pharmaceutical composition is suitable for industrial production.

The invention relates to a sterilizing composite containing metconazole and trifloxystrobin. The sterilizing composite containing metconazole and trifloxystrobin comprises an active component and an auxiliary component of a pesticide preparation, wherein the active component comprises metconazole and trifloxystrobin according to the weight ratio of 1:0.03-30, and the active component accounts for no more than 85% of the weight content of the sterilizing composite. In the sterilizing composite, the metconazole and the trifloxystrobin with different mechanisms of action are compounded, and have an obvious synergistic effect. The sterilizing composite has the advantages that the control effect of the sterilizing composite is obvious, the resistance is lowered and delayed, and the toxicity (on the mammal) is not enhanced. In addition, the sterilizing composite provided by the invention has the advantages of small dosage, low cost of the composite and low environmental pollution.

The invention discloses pharmaceutical composition for treating or preventing obesity and metabolic syndrome and belongs to the field of pharmaceuticals. The pharmaceutical composition comprises active ingredients, namely orlistat and miglitol according to a preferable weight ratio of 1:0.1-100, and a more preferable weight ratio of 1:0.5-10. The pharmaceutical composition can be made into conventional pharmaceutical dosage forms, preferably the solid form. The pharmaceutical composition has evident synergistic effect on treating or preventing obesity and metabolic syndrome, is capable of lowering the risks of cardiovascular diseases and has broad medical application prospect.

The invention discloses a medical composition for losing weight or treating hyperlipidemia, belonging to the field of medicines, and in particular relates to a medical composition containing orlistat or cetilistat and rosuvastatin calcium, wherein the composition is solid preparations such as compressed tablets, dispersible tablets, sustained release tablets, capsules, granules, and the like. In experiments, the medical composition containing the orlistat or the cetilistat and the rosuvastatin calcium is accidentally found to have obvious synergistic effect on the aspects of reducing the serum total cholesterol, the serum triglyceride and the low density lipoprotein cholesterin.

The present invention provides a new drug treatment composition for treating hyperlipidemia, which is charactered in that it contains an effective volume of Acipimox and Simvastatin, and it has a weight ratio of (10 ~ 80): 1, a preferable weight ratio of (10 ~ 40): 1, and further preferable weight ratio of 15:1. Its lipid-lowering effect is superior to the same dose of signal prescription, which indicates the two drugs have synergistic effects, and at the same time have no obvious toxicity.

The invention discloses a pharmaceutical composition used for preventing and controlling a metabolic syndrome and application thereof. Active components of the pharmaceutical composition comprise: (1) aliskiren or a pharmaceutically acceptable salt thereof; and (2) ligustrazine phosphate. The composition provided by the invention has same effects on reduction of blood pressure, blood fat, blood sugar and body weight as each active component of the composition does; compatible usage of the two active components enables the dosage of each individual component to be greatly reduced, so adverse reaction of aliskiren and drug risk of ligustrazine phosphate are substantially reduced.